(Reuters) – Biogen Inc said on Monday the U.S. Food and Drug Administration had extended the review of its experimental treatment for an inherited form of amyotrophic lateral sclerosis (ALS) by three months.
The company said the new target action date provided by the agency is April 25, 2023.
(Reporting by Bhanvi Satija in Bengaluru; Editing by Devika Syamnath)
